IPOPLUS

₹1,051

▲ +6.2 +0.59%

17 Jun 2026

NSE Listed · Pharmaceuticals

Alivus Life Sciences Ltd. (ALIVUS)

Volume: 9,070Avg Vol 1W: 57,628Avg Vol 1M: 56,54552W Range:₹819₹1,148.4
NSE BSE www.alivus.com
₹1,051▲ 0.59%
Key Ratios
Updated 3h ago
Market Cap—
Current Price₹1,051
Previous Close₹1,044.8
High / Low (52w)₹1,148.4 / ₹819
Volume9,070
Avg Vol (1W)57,628
Avg Vol (1M)56,545
Stock P/E—
Book Value₹271.46
Dividend Yield—
ROE—
ROA—
Revenue (TTM)₹2,552 Cr
Revenue Growth—
Profit Margin—
Total Debt—
Shares Outstanding—
Face Value₹2
EPS (TTM)₹13.23
P/B3.84
Debt / Equity—
50 DMA₹1,052.07
200 DMA₹988.95
Day change+0.59%
Price Chart
₹1,051▲ 14.27% · 1Y
₹1126₹85617.0L
2025-10-20
2026-06-16

20-day avg volume: 56K shares

Pros
  • Net profit is growing year over year.
Quarterly Results
MetricMar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022Mar 2022Dec 2021Sept 2021Jun 2021Mar 2021Dec 2020Sept 2020Jun 2020
Revenue₹689 Cr₹673 Cr₹0 Cr₹602 Cr₹650 Cr₹642 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
EBITDA₹194 Cr₹212 Cr₹0 Cr₹155 Cr₹182 Cr₹175 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Net Profit₹163 Cr₹150 Cr₹0 Cr₹122 Cr₹142 Cr₹137 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
EPS13.2212.2210.589.8811.5511.147.759.087.979.679.6911.0511.948.578.728.878.078.659.829.369.718.666.727.52
Profit & Loss (Annual)
MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Revenue₹2,552 Cr₹2,387 Cr₹2,283 Cr₹2,161 Cr₹0 Cr₹0 Cr₹0 Cr
EBITDA₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Net Profit₹564 Cr₹486 Cr₹471 Cr₹467 Cr₹0 Cr₹0 Cr₹0 Cr
EPS————35.6332.6129.04
Balance Sheet
MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Total Assets₹3,983 Cr₹3,411 Cr₹2,850 Cr₹2,702 Cr₹0 Cr₹0 Cr₹0 Cr
Total Liabilities₹651 Cr₹594 Cr₹518 Cr₹564 Cr₹0 Cr₹0 Cr₹0 Cr
Equity₹3,332 Cr₹2,817 Cr₹2,332 Cr₹2,138 Cr₹0 Cr₹0 Cr₹0 Cr
Total Debt₹57 Cr₹57 Cr₹17 Cr₹19 Cr₹0 Cr₹0 Cr₹0 Cr
Cash Flow
MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Operating₹565 Cr₹392 Cr₹414 Cr₹306 Cr₹0 Cr₹0 Cr
Investing₹-570 Cr₹-616 Cr₹-116 Cr₹-147 Cr₹0 Cr₹0 Cr
Financing₹-64 Cr₹-6 Cr₹-279 Cr₹-388 Cr₹0 Cr₹0 Cr
Free Cash Flow₹258 Cr₹225 Cr₹285 Cr₹143 Cr₹0 Cr₹0 Cr
Shareholding
Promoter 74.87% Institutions 12.57% Public 12.56%
About Alivus Life Sciences Ltd.

Pharmaceuticals · Pharmaceuticals - Indian - Bulk Drugs & Formln

Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search